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Retail Druggist's Warranty of Drugs
Thomas M. Schmitz*
S HORTLY AFTER THE TURN OF THE CENTURY homemakers were
shocked by public disclosures of filthy, fraudulent, and
dangerous products being sold for general human consumption.
Use of these products resulted in tragic consequences when
people believed in the cure-all promises of some of the "patent"
medicines. Such conditions led to the enactment of the Pure
Food and Drug Law of 1906.1 In 1938 there was great public
outcry for public protection following the Elixir Sulfanilamide
disaster which resulted in 107 deaths due to the use of that
drug. This tragic episode resulted in the greatly revised Food,
Drug and Cosmetic Act of 1938.2 Currently the United States
government, the drug industry, and the medical profession are
in the midst of an all-out drive against medicines that can hurt
as well as heal.3 This vigorously stepped-up drive for drug
safety began three years ago following America's close brush
with disaster involving the sedative drug, Thalidomide. 4 While
the William S. Merrell Company's application to market the drug
was still pending before the Food and Drug Administration
(FDA), a dreadful tragedy was developing in Europe. Germany
alone reported 5,000 to 6,000 phocomelic births (malformed arms
and legs) within a period of three to five years.5 Public clamor
again grew for strengthened protection, and this resulted in the
Kefauver-Harris Drug Amendments of 1962.6
In recent months the FDA and the drug industry have be-
come the subjects of front page news.7 One outspoken article
* B.S., Case Inst. of Tech.; Registered Profesional Engineer in Ohio; Third-
year student at Cleveland-Marshall Law School of Baldwin-Wallace Col-
lege.
1 U. S. Department of Health, Education, and Welfare, Food and Drug
Admin., Publication No. 1, revised 1965, p. 1.
2 U. S. Department of Health, Education, and Welfare, Food and Drug
Admin., Student Reference Sheet--3, 1964, p. 1.
3 David, "Drug Detectives," The Cleveland Plain Dealer, This Week Maga-
zine (Oct. 25, 1965), p. 6.
4 Ibid.
5 U. S. Department of Health, Education, and Welfare, Food and Drug
Admin., op. cit. supra note 2.
6 Ibid.
7 "Birth Control Pills to Undergo Full Probe," The Cleveland Press, Home
Edition (Nov. 18, 1965), p. 1.
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charged that the drug companies market laboratory "failures"
as new products to make quick profits, thus abusing the trust
of prescribing physicians. This same article concludes that if the
physicians are hoodwinked, individually or collectively, it re-
mains for the patient to pay and to suffer.8
In light of the current controversy and public interest,
serious study should be afforded as to whether "it remains for
the patient to pay." All individuals closely connected with the
manufacturing, retailing, or prescribing of drugs should have re-
sponsible knowledge of the legal liability of injurious after-
effects of public consumption of harmful drugs.
Drug manufacturers must maintain high standard of care in
conforming to stringent FDA specifications in the marketing of
all drugs9 and in providing adequate warnings in the sale of
new drugs. 10 Manufacturers are generally considered to have
absolute liability to the ultimate consumer, thus negating a con-
tractual privity requirement." Due to the dangerous propensi-
ties of drugs, the physician is required to adhere to a high
standard of care in prescribing them for his patients. 12
The retail druggist occupies the precarious position of being
closest in privity to the ultimate consumer, but very often he
is devoid of negligence in contributing to an injury. He merely
serves as a conduit in the channels of commerce in drug retail-
ing. The standard of care required of the retail druggist is that
of the highest degree and must be maintained in order to pre-
vent injuries to the public resulting from the necessary use of
(Continued from preceding page)
"Phoney-Pill Laws Gather Cobwebs," The Cleveland Plain Dealer (Oct.
26, 1965), p. 1.
"Drug Snafus Blamed on FDA Mishandling," The Cleveland Press,
Home Edition (Oct. 25, 1965), p. A4.
"The Nightmare Drug," The Cleveland Plain Dealer, This Week Maga-
zine (Jan. 9, 1966), p. 7.
s Seitz, "The Drug Nightmare They Don't Talk About," The Cleveland
Press, Home Edition (Nov. 19, 1965), p. 15.
9 U. S. Department of Health, Education, and Welfare, Food and Drug
Admin., Publication No. 5, 1963, p. 1.
10 Rheingold, "Products Liability-The Ethical Drug Manufacturer's Lia-
bility," 18 Rutgers L. Rev. 947 (1964).
11 Jaeger, "Warranties of Merchantability and Fitness for Use: Recent De-
velopments," 16 Rutgers L. Rev. 493 (1962).
12 Haggins, "Due Care by Physicians in Use of New Drugs," 14 Clev.-Mar.




drugs.13 When lack of due care is evident, an action may lie in
negligence.14
Liability for negligence is predominantly superseded by li-
ability for breach of warranty. A forerunner of contemporary
warranty liability for the sale of defective drugs was recognized
as early as 1852.15 In this early case it was held that a whole-
saler who carelessly labels deadly poison as a harmless medicine
is liable to any person injured thereby, even though it has passed
through other hands by intermediate sales.16 Warranty gradually
came to be regarded as a term of contract of sale within the
Sales Acts.17
Reliance on Retailer's Judgment
Actionable causes were usually based on a representation by
the seller inducing the sale, and a reliance on that representa-
tion by the buyer.'s A retail druggist representing sweet oil
to be of good quality when, in fact, the oil was rancid, was held
liable for breach of an express warranty in contract. 19 Liability
for a poisonous lipstick selected and recommended for the in-
tended purpose by a sales clerk was dependent upon reliance on
the retailer's judgment and skill. 20 An allergy did not preclude
recovery if it was evident that the purchaser relied on the re-
tailer's judgment. 21 A sealed package containing a defective cos-
metic would not except a retail druggist from liability if, in
fact, there was reliance.22 A cosmetic used in accordance with
written instructions brought liability on a retail druggist due to
13 Knoefel v. Atkins, 40 Ind. App. 428, 81 N. E. 600 (1907).
Willson v. Faxon, 208 N. Y. 108, 101 N. E. 799 (1913).
14 Commissioners of State Ins. Fund v. City Chemical Corp., 290 N. Y. 64,
48 N. E. 2d 262 (1943).
Willson v. Faxon, supra note 13.
Johnson v. Primm, Rexall Drug, 74 N. Mex. 597, 396 P. 2d 426 (1964).
15 Thomas v. Winchester, 6 N. Y. 397 (N. Y. App. 1852).
16 Ibid.
17 Spry v. Kiser, 179 N. C. 417, 102 S. E. 708 (1920).
18 Uniform Sales Act, secs. 12, 15 (1).
Unif. Commercial Code 2-313, 2-315.
19 Spry v. Kiser, supra note 17.
20 Reynolds v. Sun Ray Drug Co., 135 N. J. L. 475, 52 A. 2d 666 (1947).
21 Kurriss v. Conrad and Co., 312 Mass. 699, 46 N. E. 2d 12 (1942).
Reynolds v. Sun Ray Drug Co., supra note 20.
22 Bel v. Adler, 63 Geo. App. 473, 11 S. E. 2d 495 (1940).
Davis v. Radford, 233 N. C. 283, 63 S. E. 2d 822 (1951).
Griggs Canning Co. v. Josey, 139 Tex. 623, 164 S. W. 2d 835 (1942).
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his representation that the cosmetic was safe when however, it
contained a harmful chemical. 23 There is some authority that
minimizes reliance on the retail druggist's judgment and skill
if the drug was sold by trade name.24 This view has been nar-
rowly limited and distinguished on the basis that there must
be reliance on the manufacturer's reputation, as opposed to re-
liance on the retail druggist. 25 One interesting case held that a
trade name cosmetic recommended by a retailer was merely
warranted to be a product of a reputable manufacturer. 26 A re-
cent case relieved a retail druggist from liability for unknown
and unforeseen side effects due to the ingestion of a prescrip-
tion drug since the purchaser-patient relied on the physician's
judgment and knowledge and did not rely on the retailer.27 A
retail druggist who sells a prescription drug warrants that he
has compounded the drug prescribed, that proper methods were
used in the compounding process, that he has used due and
proper care in filling the prescription, and that the drug has
not been affected with some adulterating substance.28
Fitness and Merchantability
A phase of retailer's warranty of drugs has often been ex-
pressed as a contractual warranty of "fitness for a particular
purpose," 29 and a warranty of "merchantable quality in a sale
by description." 30 A cosmetic containing a known skin irritant
was impliedly warranted by a retail druggist to be fit for the
particular purpose intended,3 1 namely, human use.32 Sale of a
patented salt substitute sold in the original package brought
liability upon a retail druggist for breach of implied warranty
of wholesomeness of a product for human consumption.3 3 It ap-
pears, however, that liability is not necessarily confined to human
23 Schilling v. Roux Distributing Co. Inc., 240 Minn. 71, 59 N. W. 2d 907
(1953).
24 Williams v. S. H. Kress Co., 48 Wash. 2d 88, 291 P. 2d 662 (1955).
25 Esborg v. Bailey Drug Co., 61 Wash. 2d 347, 378 P. 2d 298 (1963).
26 Bel v. Adler, supra note 22. The opinion neglected to cite a standard for
identifying reputable manufacturers.
27 McLeod v. W. S. Merrell Co., 174 S. 2d 736 (Sup. Ct. of Fla. 1965).
28 Ibid.
29 Unif. Sales Act, sec. 15; Unif. Commercial Code 2-315.
30 Unif. Sales Act, sec. 15; Unif. Commercial Code 2-314.
31 Bianchi v. Denholm & McKay Co., 302 Mass. 469, 19 N. E. 2d 697 (1939).
32 Crotty v. Shartenberg's-New Haven, Inc., 147 Conn. 460, 162 A. 2d 513
(1960).




use or consumption. A retail druggist breached a warranty of
fitness for the purpose intended by selling a drug which caused
the death of a dog. 34 A retailer's lack of knowledge of unfitness
or unwholesomeness appears to be irrelevant. 35 A lipstick caus-
ing a skin infection was impliedly warranted by a retail drug-
gist to be reasonably fit for the intended use.3 6 It seems rather
certain that courts are not inclined to find liability where ade-
quate warnings have been given,37 or where only an isolated few
are allergic.
A retail druggist warrants the merchantability of poten-
tially harmful drugs and cosmetics which are available for gen-
eral human use.38 A recent case, however, held that a warranty
of merchantability did not apply to a prescription drug because
the drug was not available to the general public; and a warranty
of fitness was not applicable because the patient relied on his
physician's judgment rather than the retail druggist's advice.3 9
Inequities of Contractual Warranty
Since most of the early cases were based on contractual
warranty, contract defenses have been interjected with some
success. A retail druggist was held to have no duty to open and
inspect a sealed package even though its contents may be
deleterious and unfit for human consumption.40 Lack of fore-
34 Wilcox v. Butt's Drug Stores, Inc., 38 N. Mex. 502, 35 P. 2d 978 (1934).
35 Bianchi v. Denholm & McKay Co., supra note 31.
Green v. American Tobacco Co., 325 F. 2d 673 (5th Cir. 1963).
36 Smith v. Burdine's Inc., 144 Fla. 500, 198 S. 223 (1940).
Reynolds v. Sun Ray Drug Co., supra note 20.
37 Webb v. Sandoz Chemical Works Inc., 85 Geo. App. 405, 69 S. E. 2d 689
(1952). There was no liability for a proprietary drug since there was a
warning printed on the label.
Crotty v. Shartenberg's-New Haven Inc., supra note 32.
Casagrande v. F. W. Woolworth, Inc., 340 Mass. 552, 165 N. E. 2d 109
(1960).
Jacquot v. Wm. Filene's Sons Co., 337 Mass. 312, 149 N. E. 2d 635 (1958).
38 Casagrande v. F. W. Woolworth, supra note 37. Drugs mislabelled by the
wholesaler have occasionally excused the retail druggist from liability, un-
less he held himself out as the manufacturer.
Commissioners of State Ins. Fund v. City Chemical Corp., supra note
14. A retailer attaching his own label to a drug still in the wholesaler's
original container assumed a responsibility equivalent to that of a manu-
facturer.
Tiedje v. Haney, 239 N. W. 611 (Sup. Ct. of Minn. 1931).
39 McLeod v. W. S. Merrell Co., supra note 27.
40 In Howards v. Jacobs' Pharmacy Co., 55 Geo. App. 163, 189 S. E. 373
(1937).
Bel v. Adler, supra note 22.
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seeability relieved a retailer from liability for the sale of a
harmful cosmetic which caused dermatitis.4  A purchaser having
an equal opportunity to inspect precluded recovery for a defec-
tive douche tube.42 Lack of timely notice required by the Sales
Acts has precluded recovery for breach of warranty.43 A de-
fense that the one injured was not the purchaser and therefore,
lacked privity with the retailer has been sustained.44 A de-
cedent's representative could not sustain an action for wrongful
death caused by a prescription drug. The opinion stated that
wrongful death statutes were designed to support actions ex
delicto and not ex contracto.45
Strict Liability
The current trend in product liability cases is to distinguish
between liability in tort and liability in contract.46 Implied war-
ranty in contract is increasingly becoming superseded by strict
liability in tort,47 without resort to the laws or restrictions of
contractual warranty.48 The warranty in tort concept is very
much supported by strong argument advanced by the courts
which have extended product warranties from the manufacturer
to the ultimate consumer, in absence of any privity of con-
tract.49 Public interest in human life and safety demands the
maximum possible protection against dangerous defects in prod-
ucts which consumers must buy.50 Public policy demands that
41 Bennett v. Pilot Products Co., 120 Utah 474, 235 P. 2d 525 (1951).
42 Harrington v. Montgomery Drug Co., 111 Mont. 564, Ill P. 2d 808 (1941).
43 Perry v. Thrifty Drug Co., 186 Cal. App. 2d 410, 9 Cal. Rptr. 50 (1960).
Whitfield v. Jessup, 183 P. 2d 133 (Cal. App. 1947). On appeal, held
that notice within the Sales Acts was applicable to products for human con-
sumption, but reversed the lower court holding that the notice given was
not within a reasonable time. 31 Cal. 2d 826, 193 P. 2d 1 (1948).
44 Burgess v. Sanitary Meat Market, 121 W. Va. 605, 5 S. E. 2d 785 (1939).
Hanback v. Dutch Bakery Boy, Inc., 107 F. 2d 203 (D. C., D. C. 1939).
45 Whiteley v. Webb's City Inc., 55 S. 2d 730 (Sup. Ct. of Fla. 1951). An
amendment to the Florida statute in question was held in a subsequent
case to include ex contractu, but not to include a right of action by a par-
ent for the wrongful death of a minor.
Latimer v. Sears Roebuck, 285 F. 2d 152 (5th Cir. 1960).
46 Reed v. Swift Co., 14 F. R. D. 145 (W. D. Mo. 1953).
47 Prosser, Law of Torts, 681 (3rd ed., 1964).
48 Restatement (Second), Torts, sec. 402 A, Comment M (1965).
49 Jaegar, supra note 11.
50 Restatement (Second), Torts, sec. 402 A, Comment C (1965).




the burden of accidental injuries caused by products intended
for consumption be placed upon those who market them.5 '
As indicated above, the inception of strict liability is an out-
growth of the food laws and is based on the human consumption
theory.5 2 There is no reason why this theory of strict liability
should not include drugs.53 This would tend to make the retail
druggist an insurer of the safety of the product, even though he
had exercised all reasonable care.54 This liability without fault
has been criticized in the past as putting small business men in
the constant jeopardy of being run out of business. 55 This argu-
ment, however, is very weak in comparison to the opposite re-
sult of "leaving the patient to pay." 50 Strict liability has not
made small food dealers extinct, but it has forced all food re-
tailers to exert the highest duty of care expected of them. Thus,
placing a similar strict liability on the retail druggist will like-
wise urge him to exercise the highest duty of care commensurate
with his superior knowledge and justify the trust placed in him
by the public.57
It is settled law in most jurisdictions that retailers may
transfer the real liability to the manufacturer responsible58 by
proper joinder.59
Retailers are in a position to transfer their losses to the pub-
lic in general as part of their cost of doing business.60 The pub-
lic should not be required to individually bear the hardships of
unfortunate adverse reactions to drugs.'
51 Restatement, ibid.
52 Griggs Canning Co. v. Josey, supra note 22. Leading case on food re-
tailed in sealed containers. Liability is inferred from public policy demand-
ing the protection of public health.
53 Frumer and Friedman, Products Liability sec. 32.02, at 229 (1965).
54 McLeod v. W. S. Merrell, supra note 27.
55 Sencer v. Carl's Markets, Inc., 45 S. 2d 671 (Sup. Ct. of Fla. 1950).
Rheingold, op. cit. supra note 10, p. 1016-1017. The idea is expressed
that it is hard to imagine any drug company whose financial situation is
so marginal so as to be unable to purchase insurance. If a particular re-
tailer should fall into financial difficulty, it would be difficult to show that
the public would thereby be the loser.
56 Seitz, op. cit. supra note 8.
57 Restatement, op. cit. supra note 50. (1965).
58 McSpedon v. Kunz, 271 N. Y. 131, 2 N. E. 2d 513 (1936).
59 Davis v. Radford, supra note 22;
Monks v. Jaxon Corp., 17 Conn. Supp. 32 (1950);
Brown v. Hersch Chemists Inc., 305 N. Y. 755, 113 N. E. 2d 151 (1953).
60 Prosser, op. cit. supra note 47, p. 509.
61 Rheingold, op. cit. supra note 10 at p. 1017. "Clearest of all is the prop-
osition that the ultimate loss should not be borne by the individual who
suffers a devastating reaction to a drug."
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In this age when it seems fashionable for the retail druggist
to advertise the lowest discount prices in town, there is a constant
threat of fraudulent and counterfeit drug peddling to the re-
tailers at reduced wholesale prices. 62 These drugs are potentially
dangerous because they are not manufactured under rigid FDA
controls.63 Thus, it behooves a drug retailer to deal only with
legitimate wholesalers64 and wholesalers who may be properly
joined in event of a damage suit against the retailer.65 It would
seem that retail druggists should be put on notice of a whole-
saler's reputation if an individual wholesaler is prone to market-
ing unsafe drugs", or prone to dishonest dealing with the
FDA.67 This should be, if the public health is to be protected
from exploitation by those who, for the profit motive, under-
take to supply products for human consumption.0 s From the
nature of the industry the primary motive for marketing a drug
should be to further public health. Thus, the Restatement's re-
quirement of retailers to deal with reputable wholesalers 9 is
very much applicable to drug retailing.
The phase of drug retailing described as "new drugs" raises
a particularly difficult problem. New drugs are defined as
"drugs not generally recognized as safe and effective by quali-
fied experts." 70 Most new drugs are released for prescription
sale only, and the labeling of the consumer package must then
contain adequate directions and warnings.7 1
62 David, op. cit. supra note 3, p. 7.
63 Ibid.
64 Restatement (Second), Torts, Sec. 401, Comment C (1965).
65 Sencer v. Carl's Market, supra note 55.
66 McLeod v. W. S. Merrell Co., supra note 27. W. S. Merrell Company was
also responsible for distributing Thalidomide in the United States, op. cit.
supra note 5. Consider that W. S. Merrell Company marketed "Mer/29"
which caused serious side effects.
67 Haggins, op. cit. supra note 12 at p. 511. "In March 1964, the Merrell
Company went on trial with three of its executives, and its parent company,
Richardson-Merrell Inc., on twelve counts of supplying the Food and Drug
Administration with false, fictitious and fraudulent data. The company and
its executives pleaded nolo contendere on eight counts."
68 Green v. American Tobacco Co., supra note 35.
Seitz, op. cit. supra note 8. "This is an age in which manufacturers are
tempted to get to the market first with a new drug, however inadequately
it has been tested for safety and efficacy, or to rush an imitation into the
pharmacies when a competitor seems to have a good thing going."
69 Restatement, op. cit. supra, note 64.
70 Op. cit. supra note 9, p. 1.




A definite distinction must be made between new drugs and
experimental drugs. Experimental drugs are not released for
marketing, but they are distributed to specified physicians
under very strict supervision of FDA laws.72 The 1962 amend-
ment requires the physician to inform the patient of the experi-
mental nature of the drug.7 3 In all probability, there is no strict
liability for the injurious effects of an experimental drug if an
appropriate warning has been given to the patient.7 4 Thus, the
law recognizes that medical research must progress.
The Restatement accepts "a medically recognizable risk"
involved in the marketing of experimental and new drugs75 and
uses the Pasteur vaccine treatment of rabies as an illustration.
The disease itself leads invariably to a dreadful death; thus, the
use of the vaccine on a person imminently threatened with
rabies is fully justified notwithstanding the unavoidable high
degree of risk involved.76 The interpretation of the Restatement
must be construed within the FDA requirement that the use-
fulness of the drug must outweigh its hazards. 7 7 The Restate-
ment requires further that the experimental or new drug must
contain proper warnings of potential dangers as required by
FDA laws.78 This warning in conjunction with usefulness out-
weighing hazards may then be construed as relieving the retail
druggist of liability based on the patient-consumer "assuming
the risk." An assumption of risk defense is generally sustained
in an action for strict liability.7 9
A recent case considered the liability of a retail druggist for
the sale of a prescription drug, "Mer/29," which inadvertently
resulted in injurious side effects.80 A physician prescribed the
drug for the control of body cholesterol. Upon using the drug,
however, the patient developed cataracts of his eyes. Dictum in-
72 Id., p. 6-8. Each physician must keep complete records and case histories
of his use of the experimental drug and file a report.
73 Id., p. 8.
74 Prosser, op. cit. supra note 47, p. 683. Id., p. 6. Due to the strict controls
on experimental drugs, a retail druggist will essentially not be confronted
with liability arising from their use.
75 Restatement (Second), Torts Sec. 402A, Comment K (1965).
76 Ibid.
77 David, op. cit. supra note 3.
78 Restatement, op. cit. supra note 75. op. cit. supra note 9, p. 2.
79 Prosser, op. cit. supra note 47, p. 539.
80 McLeod v. W. S. Merrell, supra note 27.
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dicated the court considered the strict liability theory in ar-
riving at its decision within the Florida law of construing
product liability within the contractual warranty concept. The
court supported its decision by quoting the American Law Insti-
tute's strict liability rule.s1 The opinion cites as an exception
from the strict liability concept various new or experimental
drugs which, because of lack of time and opportunity to ob-
tain sufficient medical experience, cannot be considered as being
absolutely safe for human consumption although available ex-
perience justified the marketing and use of the drug notwith-
standing a medically recognizable risk.8 2
It is worthy to note that the court neglected to weigh all
factors related to this section of the Restatement. The Restate-
ment distinctly qualifies the suggested exception to strict li-
ability by requiring that proper warnings be given, that the in-
juries incurred were within a reasonable risk, 3 and that the
retail druggist purchased the drugs from a reputable dealer.8 4
The court did not consider whether the drug's usefulness out-
weighed its hazards.8 5
All these factors must be considered in balancing the equities
of a patient's injuries against the justification of retailing a drug
which has a medically recognizable risk.
Conclusion
Jurisdictions retaining a contractual warranty theory hold
that a retail druggist warrants the wholesomeness, fitness, and
merchantability of his products. This warranty applies to all
drugs whether they are prescription drugs, proprietary drugs,
brand name drugs, or drugs sold in the original sealed containers.
81 Restatement, op. cit. supra note 75.
82 McLeod v. W. S. Merrell, supra note 27.
Restatement, op. cit. supra note 75. "Because of lack of time and op-
portunity for sufficient medical experience" is an unfortunate sequence of
words since it suggests a minimum of testing is all that is required to jus-
tify marketing a drug. This phrase must be narrowly construed in light of
subsequent passages in the same sentence. "Absolute safeness" and a
"medically recognizable risk" implies a remote and minor injury, rather
than serious injuries affecting many users.
83 Restatement, op. cit. supra note 75.
84 Restatement, op. cit. supra note 64.
85 Op. cit. supra note 76. The threat of elevated body cholesterol seems
rather minor and the danger remote compared with a side effect of cata-
racts of the eyes. Consider "usefulness outweighing its hazards" within
the Restatement's example of the Pasteur vaccine, where the disease itself
leads to a dreadful death.
May, 1966
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Liability for the sale of a prescription drug may be exempted
if the patient relies on the physician's judgment, and liability for
the sale of a brand name drug may be relieved if there is re-
liance on the manufacturer's reputation.
Jurisdictions construing product warranty as a strict liability
in tort will invariably hold a retail druggist liable for side ef-
fects incurred by the use of drugs. The good expected to be ac-
complished must not be overshadowed by harmful side effects,
not reasonably expect to incur. Adequate warnings properly
made known to the patient may exempt the retailer from liability
and the side effects must not be of a nature that a patient would
on the basis of the patient assuming the risk.
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